硫普罗宁与甘草酸二铵治疗肝脏疾病的最小成本分析

Tiopronin and Diammonium Glycyrrhizinate for Hepatic Diseases:Cost-minimization Analysis

目的:评价硫普罗宁、甘草酸二铵单用及合用治疗肝脏疾病的经济学效果。方法:采用回顾性调查方法,按治疗方案不同分为硫普罗宁(A,n=20)、甘草酸二铵(B,n=20)、两药合用(C,n=32)3组,疗程平均分别为28.15、42.95、38.12d,观察各组疗效并运用药物经济学方法进行分析。结果:A、B、C组总有效率无显著性差异,分别为100.0%、100.0%、96.9%。A、B、C组总成本分别为(2746.02±962.49)、(3099.95±1548.95)、(4166.68±2131.86)元,A组与B组成本无显著性差异,C组成本最高。B组优点为显效率高(70.0%),A、C组分别为50.0%、59.4%;B组缺点为若药品费用下降或药品费用下降同时误工费用上调则总成本相对上升较多。结论:A组与B组均为较佳方案,其中A组最佳,C组为最差方案。

OBJECTIVE： To evaluate the economic effects of tiopronin and diammonium glycyrrhizinate alone or in combination for hepatic diseases. METHODS： In this retrospective study, patients were assigned to receive tiopronin （A, n = 20） for an average of 28.15 days, Diammoniurn glycyrrhizinate （B, n = 20） average of 42.95 days or tiopronin plus diammonium glycyrrhizinate （C, n = 32） for an average of 38.12 days. The clinical efficacy was observed and pharmacoeconomie analysis was carried out. RESULTS： The total effective rates of A, B, and C groups were 100.0% , 100.0% and 96.9% , respectively, showing no significant difference among the three groups. The total costs were 2 746.02 ± 962.49, 3 099.95± 1 548.95 and 4 166.68±2 131.86 yuan, respectively, showing no significant difference in cost between Group A and B, while Group C has the highest cost. Group B has the highest significant effective rate of 70.0% versus 50.0% of Group A and 59.4% of Group C. However, the total cost for Group B rises correspondingly if the cost of all the drugs descends and/ or if charge for loss of working time goes up. CONCLUSION： Group A is preferable, followed by Group B; however, Group C is the worst.